Colette Muenzen

Colette Muenzen has held the role of Senior Legal Consultant at Glycomine Inc., Escient Pharmaceuticals, Antiva Biosciences, Inc., Aurion Biotech, Astellas Pharma US, Providence Medical Technology, Inc., Astellas Gene Therapies, Prothelia, and Modis Therapeutics, Inc. since 2022, 2021, 2021, 2021, 2019, 2014, 2020, 2021, and 2018 respectively.

Colette Muenzen obtained their JD in Intellectual Property Law from UNH Franklin Pierce School of Law, their BA in Chemistry/Biochemistry from Wellesley College, and studied Biology at Cornell University. In 1996, they were registered to practice before the U.S. Patent and Trademark Office # 39,784 and in 1995, they were admitted to practice in NJ, PA and Washington, D.C.